埃博拉病毒病治疗药物的随机对照试验
在刚果民主共和国埃博拉病毒病暴发期间,将681例埃博拉病毒RNA检测阳性患者按1:1:1:1随机分配接受ZMapp、瑞德西韦、MAb114或REGN-EB3治疗。28天死亡率MAb114组35.1%低于ZMapp组49.7%(P=0.007),REGN-EB3组33.5%低于ZMapp亚组51.3%(P=0.002)。MAb114和REGN-EB3在降低埃博拉病毒病死亡率方面均优于ZMapp。
要点
- MAb114组28天死亡率35.1%,低于ZMapp组的49.7%(P=0.007)。
- REGN-EB3组28天死亡率33.5%,低于ZMapp亚组的51.3%(P=0.002)。
- 入院前症状持续时间较短及病毒载量、血清肌酐和转氨酶基线值较低与生存改善相关。
核心结论
- MAb114和REGN-EB3在降低埃博拉病毒病死亡率方面均优于ZMapp。
- 在疾病暴发期间可以开展科学和伦理上合理的临床研究,并有助于指导疫情应对。
研究设计与样本
- 在刚果民主共和国开展四种研究性疗法治疗埃博拉病毒病的随机对照试验,2018年8月暴发疫情。
- 任何年龄且逆转录-聚合酶链反应检测埃博拉病毒RNA阳性的患者入组,所有患者接受标准治疗。
- 患者按1:1:1:1比例随机分配接受静脉给予ZMapp(对照组)、瑞德西韦、MAb114或REGN-EB3。
- REGN-EB3组在方案后期版本中加入,其数据与REGN-EB3组加入时或之后入组的ZMapp组患者(ZMapp亚组)比较。
- 2018年11月20日至2019年8月9日共入组681例患者。
主要发现
- 28天时,MAb114组174例中61例死亡(35.1%),ZMapp组169例中84例死亡(49.7%)(P=0.007)。
- 28天时,REGN-EB3组155例中52例死亡(33.5%),ZMapp亚组154例中79例死亡(51.3%)(P=0.002)。
- 入院前症状持续时间较短以及病毒载量、血清肌酐和转氨酶基线值较低均与生存改善相关。
- 4例严重不良事件被判定可能与试验药物相关。
- 中期分析显示MAb114和REGN-EB3在死亡率方面优于ZMapp和瑞德西韦,数据与安全监察委员会据此建议试验剩余部分仅将患者分配至MAb114和REGN-EB3组。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although several experimental therapeutics for Ebola virus disease (EVD) have been developed, the safety and efficacy of the most promising therapies need to be assessed in the context of a randomized, controlled trial. METHODS: We conducted a trial of four investigational therapies for EVD in the Democratic Republic of Congo, where an outbreak began in August 2018. Patients of any age who had a positive result for Ebola virus RNA on reverse-transcriptase-polymerase-chain-reaction assay were enrolled. All patients received standard care and were randomly assigned in a 1:1:1:1 ratio to intravenous administration of the triple monoclonal antibody ZMapp (the control group), the antiviral agent remdesivir, the single monoclonal antibody MAb114, or the triple monoclonal antibody REGN-EB3. The REGN-EB3 group was added in a later version of the protocol, so data from these patients were compared with those of patients in the ZMapp group who were enrolled at or after the time the REGN-EB3 group was added (the ZMapp subgroup). The primary end point was death at 28 days. RESULTS: A total of 681 patients were enrolled from November 20, 2018, to August 9, 2019, at which time the data and safety monitoring board recommended that patients be assigned only to the MAb114 and REGN-EB3 groups for the remainder of the trial; the recommendation was based on the results of an interim analysis that showed superiority of these groups to ZMapp and remdesivir with respect to mortality. At 28 days, death had occurred in 61 of 174 patients (35.1%) in the MAb114 group, as compared with 84 of 169 (49.7%) in the ZMapp group (P = 0.007), and in 52 of 155 (33.5%) in the REGN-EB3 group, as compared with 79 of 154 (51.3%) in the ZMapp subgroup (P = 0.002). A shorter duration of symptoms before admission and lower baseline values for viral load and for serum creatinine and aminotransferase levels each correlated with improved survival. Four serious adverse events were judged to be potentially related to the trial drugs. CONCLUSIONS: Both MAb114 and REGN-EB3 were superior to ZMapp in reducing mortality from EVD. Scientifically and ethically sound clinical research can be conducted during disease outbreaks and can help inform the outbreak response. (Funded by the National Institute of Allergy and Infectious Diseases and others; PALM ClinicalTrials.gov number, NCT03719586.).
引用
- Mulangu S, Dodd LE, Davey RT, et al. A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics. N Engl J Med. 2019. PMID: 31774950. doi:10.1056/NEJMoa1910993
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。